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Abstract
Purpose Fertility preservation methods are playing an
increasing role in women up to the age of 40 years because
of rising survival rates in those affected by cancer. How-
ever, balanced practical recommendations concerning all
relevant fertility preservation, to support doctors in coun-
selling and treating patients, are still rare.
Methods These recommendations were prepared by the
network FertiPROTEKT (http://www.fertiprotect.eu), a
collaboration of around 70 centres in Germany, Switzer-
land and Austria. The recommendations were developed by
specialists in reproductive medicine, reproductive biology
and oncology, which gave a comprehensive overview of all
named techniques as well as their benefits and risks. Fur-
thermore, practice-orientated recommendations for the
individual use of fertility preservation methods for various
indications such as breast cancer, Hodgkin’s lymphoma
and borderline ovarian tumours are given.
Results Various options such as ovarian stimulation and
cryopreservation of unfertilised or fertilised oocytes,
cryopreservation and transplantation of ovarian tissue,
GnRH-agonist administration and transposition of the
ovaries can be offered. All the techniques can be performed
alone or in combination within a maximum of 2 weeks
with low risk and different success rates.
Conclusions Fertility preservation in women has become
an option with realistic chances to become pregnant after
cytotoxic therapies. The information provided allows a
well balanced and realistic counselling and treatment.
Keywords Cancer  Fertility preservation  Oocytes 
Ovarian tissue  Cryopreservation  GnRH agonists
Introduction
Increasing survival rates in patients affected by oncological
disease and advances in reproductive medicine have led to
the development and increasing use of various fertility
preservation techniques. Over the last few years, several
techniques have been particularly favoured despite insuf-
ficient data and others have not been recommended.
Meanwhile however, improving data and optimisation of
the available techniques have allowed a realistic portrayal
of the efficacy and risks of the most commonly used
methods as well as recommendations for the use of the
techniques alone or in combination. Many recommenda-
tions can be found in the literature on fertility protection;
however, there is no current publication which objectively
considers all the established techniques [1, 2]. Furthermore,
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most work focuses only on the techniques as such or on
their relevance in various disease states without consider-
ing both aspects and connecting them with one another.
Recommendations from the FertiPROTEKT Network [3],
described below, were formulated for clinical practice in
such a way that not only the techniques are objectively
represented, but also recommendations for their use in
clinical practice for the commonest oncological diseases
are also given. The recommendations, developed by spe-
cialists in reproductive medicine and reproductive biolo-
gists as well as oncologists, avoid a detailed listing of all
the underlying work, and rather summarise their key
messages and reinforce them with information from current
publications or review articles. This concept allows a
comprehensive and practice-orientated description of a
complex topic and an application for specialists in repro-
ductive medicine and oncologists.
The general recommendations for the counselling on
and use of fertility preservation methods are presented
first in the following review (Fig. 1), followed by the
techniques, a description of their efficacy and risks, and
finally a discussion of their use in breast cancer, Hodg-
kin’s lymphoma and borderline ovarian tumours
(Tables 1, 2, 3 and 4).
General recommendations
• All women between the ages of ca. 14 and 40 years
who receive chemotherapy which could lead to a sig-
nificant chance of disruption to their ovarian function
should be counselled by a doctor trained in reproduc-
tive medicine on fertility preservation methods, in
agreement with the responsible oncologists.
• All applicable methods should be included in the
counselling.
• All counselling and treatments, including complications
which occur, should be documented in the records.
• Performing fertility preservation techniques, i.e. due to
the postponement of a cytotoxic therapy, must not
affect the efficacy of the oncological regimen.
Ovarian
transposition
and /or
Cryopreservation of
ovarian tissue
and /or
Ovarian stimulation
and
cryopreservation of
unfertilized or
fertilized oocytes
Ovarian stimulation
and cryopreservation
of unfertilized or
fertilized oocytes
aromatase inhibitors
and /or
Cryopreservation of
ovarian tissue
and/or
GnRH-agonists
Ovarian stimulation
and cryopreservation
of unfertilized or
fertilized oocytes
and / or
Cryopreservation of
ovarian tissue
and/or
GnRH-agonists
Cryopreservation of
ovarian tissue
and/or
GnRH-agonists
Fertility preservation of post pubertal women
Chemotherapy can
be postponed by <2 
weeks
Radiation of the
pelvis
Chemotherapy can be postponed
by 2 weeks
Tumor estrogen
dependant
Tumor not estrogen
dependant
Fig. 1 Simplified regimen for
the use of fertility preservation
procedures. It should be noted
that the choice of method also
depends on the patient’s age,
their prognosis, the toxicity of
the chemotherapy and the
individual wishes of the patient
and their partner
Table 1 Breast cancer: chemotherapy-associated amenorrhoea rate (A = doxorubicin; C = cyclophosphamide; E = epirubicin; F = 5-fluo-
rouraci; M = methotrexate (modified according to [39])
Age (years) Chemotherapy Rate of amenorrhoea (%)
[40 6 9 CMF, 6 9 FEC, 6 9 FAC [ 80 (High risk)
\40 High-dose EC
30–39 6 9 CMF, 6 9 FEC, 6 9 FAC 20–80 (Moderate risk)
[40 4 9 AC
\30 6 9 CMF, 6 9 FEC, 6 9 FAC \20 (Low risk)
\40 4 9 AC
Insufficient data: taxanes, monoclonal antibodies, avastin (bevacizumab), lapatinib, herceptin (trastuzumab) and gemzar (gemcitabine)
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Fertility protection techniques
Ovarian stimulation and cryopreservation
of unfertilised and fertilised oocytes
Indications and requirements
• Postmenarchal women up to the age of 40 years with a
sufficient ovarian reserve, who receive chemotherapy
or another treatment which could lead to a significant
chance of premature ovarian insufficiency or loss of
ovarian function
• The time until the start of chemotherapy is at least
2 weeks
Description of ovarian stimulation
• Starting stimulation during menstruation: perform a
classic GnRH-antagonist protocol, as this is associated
with a lower risk of ovarian hyperstimulation syndrome
(OHSS) [4]
• Starting stimulation in other cycle phases: GnRH-
antagonist immediately and simultaneously start
administering recombinant follicle stimulating hor-
mone (FSH) [5]
• Induction of ovulation in the case of impending OHSS
with triptorelin 0.2 mg [6]
• In the case of estrogen-dependent tumours, stimulation
can be combined with letrozole 5 mg daily [7], which is
administered at the same time as the gonadotrophin.
Description of cryopreservation of fertilised
and unfertilised oocytes
To reduce the risk of fertilisation failure, intracytoplasmic
sperm injection (ICSI) should be considered, with only jus-
tifiable exceptions, and independent of the spermiogram.
Unfertilised oocytes are preserved by slow freezing or
vitrification. According to the current data, vitrification
appears to be more effective [8, 9]. Cryopreservation of
unfertilised oocytes by vitrification should only be per-
formed when internal controls have shown that there is
technique proficiency.
Success rates
On average, 11.6 oocytes from 205 follicle punctures were
collected in the FertiPROTEKT Network (STD: ±7.7; 25%
quartile: n = 6; 75% quartile: n = 15). The fertilisation
Table 2 Breast cancer: fertility preservation procedures depending on hormone receptor status and oncological treatment plan in women with a
medium to high risk of amenorrhoea
Adjuvant situation (fertility preservation after
surgery and before chemotherapy)
Neoadjuvant situation (fertility preservation
before chemotherapy and before surgery)
Hormone
receptor
negative
Hormone
receptor
positive
Hormone
receptor
negative
Hormone
receptor
positive
Hormonal stimulation and
cryopreservation
of unfertilised and fertilised oocytes
? (?) (?) -
(± combination with
letrozole)
(± combination with
letrozole)
Cryopreservation of ovarian tissue ? ? ? ?
Combination of hormonal stimulation
and cryopreservation of oocytes
and ovarian tissue
? (?) (?) -
(± combination with
letrozole)
(± combination with
letrozole)
GnRH-agonists ? (-) ? (-)
Table 3 Hodgkin’s lymphoma—Chemotherapy-associated amenor-
rhoea rate (A = adriamycin; B = bleomycin; C = cyclophospha-
mide; E = etoposide; O = oncovin; P = procarbazine and
prednisone V = vinblastine) modified according to [40])
Age (years) Chemotherapy Rate of
amenorrhoea
(%)
C30 2 9 ABVD (HD 7, arm B) 0
5.6\30
C30 2 9 COPP/ABVD (HD 8) 12.2
3.5\30
C30 4 9 COPP/ABVD (HD 9 A) 53.3
23.5\30
C30 8 9 BEACOPP (HD 9, arm B) 42.1
11.8\30
C30 8 BEACOPP escalated (HD 9, Arm C) 70.4
40.4\30
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rate was 61.3%. If fertilisation was carried out on all
oocytes, the following number of fertilised oocytes resulted
in each age group: 18–25 years; 8.5 oocytes, 26–30 years;
7.3 oocytes, 31–35 years; 6.1 oocytes, 36–40 years; 5.1
oocytes [10, 11].
After cryopreservation of unfertilised oocytes, each
thawed, surviving egg cell had an implantation potential of
6–8%. This applies to vitrification as well as to the new and
adapted slow egg freezing protocols [9].
Risks
Significant risks are ovarian hyperstimulation syndrome
(OHSS) or the collection of immature oocytes with a low
fertilisation potential. According to the complication
records from FertiPROTEKT from 205 follicle punctures
performed, no oocytes could be preserved in three cases.
Significant overstimulation did not occur [11].
Cryopreservation of ovarian tissue
Indications and requirements
• Girls and women up to the age of ca. 35–37 years and
with an age-appropriate ovarian reserve who receive
chemotherapy or another treatment which could lead to
a significant chance of premature ovarian insufficiency
• With oncological disease: exclusion of ovarian metas-
tases using appropriate diagnostic imaging
• Exclusion of an oncological disease which is associated
with a high risk of ovarian metastases (haematological
neoplasias, metastatic breast cancer, ovarian cancer, etc.)
• The time until the start of chemotherapy is at least
3 days
• Low risk intubation of the patient and surgery is
possible (caution: mediastinal tumours in patients with
Hodgkin’s lymphoma)
Description
Removal of ovarian tissue: removal of the ovarian tissue is
performed laparoscopically where possible. The amount of
tissue removed depends on the expected probability of losing
all egg cells. Histological examination of a reference biopsy (to
exclude tumour cells, proof of follicle presence) is necessary.
Transport from operating theatre to laboratory: rapid
transport of the removed tissue is performed in transport
medium on ice. However, transport from the place of
removal to the tissue bank is also possible over a longer
period of time (\20 h) [12, 13].
Cryopreservation: the most efficient method of cryo-
preservation is currently the slow freezing technique [14].
Testing the effectiveness of the freezing method is rec-
ommended, for example by transplanting thawed tissue
into immunodeficient mice.
Retransplantation: orthotopical transplantation has—
according to the current literature—the greatest chance of
success [15]. It is still unclear which exact site should be
used for the transplant, whether a spontaneous pregnancy
or IVF should be given priority and how the patient should
be treated after the transplant. The transplantation should
in most cases be performed 2 years after the end of
treatment at the earliest, in agreement with the responsible
oncologists, when the risk of relapse has significantly
decreased.
Success rates
Fourteen births have been reported up to now. Spontaneous
pregnancies occurred as well as pregnancies after IVF
treatment. Successful teams [16] have achieved a preg-
nancy rate of ca. 30% per transplantation up to now,
although the birth rate is lower. However, other teams
report lower success rates, so it can be assumed that the
success depends on the correct indication for cryopreser-
vation, the age of the patient, the freezing technique and
the transplantation technique.
A maximum age limit of ca. 35–37 years is recom-
mended for the cryopreservation of ovarian tissue [15].
Risks
One surgical revision after laparoscopic tissue removal
from of a total of 500 laparoscopies has been documented
Table 4 Hodgkin’s lymphoma: Fertility preservation procedures for the chemotherapy regimens currently performed by the German Hodgkin’s
Society [36]
ABVD BEACOPP BEACOPP escalated
Hormonal stimulation and cryopreservation of unfertilised
and fertilised oocytes
- ? ?
Cryopreservation of ovarian tissue - ? ?
Combination of hormonal stimulation and cryopreservation
of oocytes and ovarian tissue
- ? ?
GnRH-agonists (?) ? ?
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in the FertiPROTEKT Network records [11]. A further risk
is the retransplantation of tumour tissue. Up to now,
metastases have been described in a cryoconserved speci-
men from a patient with Hodgkin’s lymphoma [17], how-
ever not with breast cancer [18].
The risk of a remetastasis after retransplantation is
unforeseeable in patients with haematological neoplasias or
a high risk of ovarian metastasis [19], therefore this should
not be performed at the present time.
GnRH-Agonists (GnRHa)
Indication
• Postmenarchal women up to the age of 40 years, who
receive chemotherapy or another treatment which could
lead to a significant chance of premature ovarian
insufficiency.
As a definitive proof of efficacy is not yet available, other
techniques should also be considered in addition to drug
treatment.
Description—GnRHa
After an initial gonadotrophin release (flare-up effect),
GnRHa bring about a downregulation of the GnRH receptor,
followed by hypogonadism. Further possible protective
mechanisms on the gonads are under discussion [20].
The flare-up effect of the GnRHa takes about 1 week;
they should therefore be administered at least 1 week
before the start of chemotherapy. If the flare-up needs to be
reduced, a GnRH-antagonist can be administered once a
day for 6 days at the same time as the GnRHa depot
injection [21]. Whether the fertility preserving effect of
GnRHa can thereby be improved has yet to be proven.
The effect of the GnRHa should continue for at least
1–2 weeks after the last chemotherapy cycle.
Success rates of GnRHa
Twelve studies carried out between 1966 and 2008 showed
that out of 234 patients who received chemotherapy, 59%
of cases had premature ovarian failure (POF) versus 9%
after a combination of chemotherapy with a GnRHa
(n = 345) [22]. A summary of nine studies (1980–2008)
confirmed these results with a POF rate of 55.5 versus
11.1% (n = 189 vs. n = 225) [20].
In 2009 and 2010, three meta-analyses were published
addressing the co-treatment GnRHa during chemotherapy to
reduce ovarian damage (23–25). Clowse et al. [23] and Ben-
Aharon et al. [24] included 8, 16 studies, respectively,
including those with retrospective controls. Clowse revealed
that GnRHa are effective in preserving ovarian function (RR
1.68) and Ben-Aharon revealed that GnRHa are effective in
reducing amenorrhoea (RR 0.26). Bedaiwy et al. [25] only
included prospective randomized studies (n = 7) with 173
patients receiving GnRHa and 167 control patients. They
calculated an odds ratio of 3.5 favouring the use of GnRHa.
On the whole, the evidence that GnRHa have a protec-
tive effect on the ovaries is becoming more established.
Nevertheless, the final conformation is still awaited.
Risks
One possible side effect of GnRH analogues is menopausal
symptoms. These symptoms are delayed, but are also
possible with chemotherapy alone. Treatment with GnRHa
for over 6 months leads to a loss of bone mass [26]. In case
of severe symptoms and in case of long term use
([6 month), add-back therapies, using low estrogen dos-
ages, can be considered. However, data concerning the
influence of add-back therapies on the fertility preserving
action of GnRHa are not available.
There is a theoretical risk of reducing the efficacy of
chemotherapy when using GnRHa in a patient with estro-
gen receptor positive breast cancer, but there is no con-
clusive evidence for or against this hypothesis. As the data
is unclear, GnRHa should not be used where estrogen
receptor positive disease is present, or should only be used
after a careful risk/benefit analysis.
Combination of the techniques
Fertility preservation procedures can be combined to
increase their efficacy (Fig. 2).
Ovarian tissue can be removed laparoscopically and
ovarian stimulation can be started ca. 1–2 days later [27]. The
theoretical chance of pregnancy is almost doubled with this
combination. Use of the luteal phase stimulation protocol is
recommended if the stimulation is stared after the fifth day of
the cycle [5]. Additional administration of an aromatase
inhibitor should be considered if breast cancer is present [7].
Short acting GnRHa are used for ovulation induction [6],
which can be combined with a GnRHa depot. Chemotherapy
can be started 1–2 days after follicle aspiration.
Starting chemotherapy before recovery of the ovaries
after stimulation did not lead to more damage to the ovaries
in an animal study [28].
Transposition of the ovaries
Indications
• Radiotherapy to the pelvis, which would lead to a
significant chance of premature ovarian insufficiency.
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Radiotherapy with two Gray leads to a loss of ca. 50% of the
primordial follicles [29]. The chance of premature ovarian
insufficiency occurring in women aged C20 years is almost
100% if they receive radiotherapy with 15 Gray [30].
Description
The mobilised ovary is usually transposed craniolaterally,
fixed and marked with clips in order to achieve the greatest
distance possible from the main irradiated area [31, 32]. As
loss of ovarian function can occur despite transposition,
additional cryopreservation of the ovarian tissue is
recommended.
Success rates
According to the published literature, there is a success rate
of up to 85% with this technique in patients with regular
ovulatory cycles, and also in patients under the age of 40
after radiotherapy [31].
Risks
Unspecific post-operative abdominal discomfort has been
described, which was a result of ovarian cysts or peritoneal
adhesions in most cases. From a group of 51 patients, sur-
gical revision was necessary in 9 of them to relieve pain [33].
Fertility preservation techniques and common
malignancies
Breast cancer
Risk of treatment-induced amenorrhoea
The risk of chemotherapy-induced amenorrhoea can only
be roughly estimated because of the limited data available.
Table 1 summarises the available studies and allows an
approximate, age-dependent estimation of the risk. There is
insufficient data for a risk calculation for taxanes, mono-
clonal antibodies, Avastin (bevacizumab), lapatinib,
Herceptin (trastuzumab) and Gemzar (gemcitabine).
Fertility protection options
The fertility protection options are shown in Table 2.
In the adjuvant situation, i.e. after tumour removal, the
time from diagnosis to the start of chemotherapy is usually
C2 weeks, therefore all available methods of fertility
preservation can be offered in theory. In the neoadjuvant
situation, ovarian stimulation should rather not be per-
formed, as the tumour is still present during stimulation.
There are insufficient data about the risk associated with
hormonal stimulation and receptor positive breast cancer.
There is a theoretical risk of tumour progression with
increased estrogen levels. However, one argument against
this is that patients who do not undergo fertility preserva-
tion treatments maintain their menstrual cycles until che-
motherapy, and therefore continue to have an endogenous
estrogen synthesis. Furthermore, a study of 91 patients who
became pregnant after recovering from breast cancer
showed no increased risk of relapse [34].
As the risk of relapse is still unclear, ovarian stimulation
in a patient with receptor positive breast cancer must be
discussed in detail with the patient after a careful risk–
benefit analysis with the responsible oncologists.
Alternatively, the stimulation treatment can be com-
bined with aromatase inhibitors [7]. The estrogen levels
increase much less with this treatment. An increased risk of
breast cancer relapse has not been found up to now in 79
patients who underwent this treatment [35]. If there are no
concerns about giving ovarian stimulation, it can be com-
bined with cryopreservation of ovarian tissue [27].
Treatment with a GnRHa should be possible without
risk in receptor-negative breast cancer patients. If receptor-
positive breast cancer is present, it cannot be ruled out that
the low estradiol values present under GnRHa treatment
could lead to a reduced tumour cell sensitivity to the
chemotherapy. However, data concerning this theory is still
lacking. As a result of this, GnRHa treatment in a patient
with receptor-positive breast cancer must be discussed in
detail with the patient after a careful risk–benefit analysis
with the responsible oncologists.
Hodgkin’s lymphoma
Risk of treatment-induced amenorrhoea
The risk of chemotherapy-induced amenorrhoea can only
be roughly estimated because of the limited data available.
GnRH-Antagonist
G
nR
Ha
Days after first consultation
Luteal phase
stimulation
Breast cancer: 
±Aromatase inhibitors
As
pi
ra
tio
n
1 ≈12 ≈14≈2
GnRH-agonist depot
ChemotherapyFSH
Cryopreservation of tissue
Fig. 2 Combination of the various fertility preservation methods to
increase the chance of pregnancy
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Table 3 allows an approximate, age-dependent estimation
of the risk.
Fertility protection options
Possible fertility preservation methods are shown in
Table 4. Only treatments which are currently carried out by
the German Hodgkin’s Study Group [36] are listed.
The risk of damage to the gonads with treatment
according to the ABVD-regimen is low, and in such a
case, fertility preservation techniques are not usually
necessary.
If the patient is undergoing treatment according to the
BEACOPP or BEACOPP-escalated regimen, an individual
and age-related risk–benefit analysis should be carried out
with the oncologists and the patient, and fertility preser-
vation treatment should be started if necessary.
If ovarian tissue is to be cryoconserved and the patient
has a mediastinal tumour, the increased anaesthesia risk
should be taken into consideration. All forms of fertility
preservation methods are otherwise possible, alone or in
combination, in a time frame of C2 weeks.
Borderline ovarian tumours
Oncological treatment
The standard treatment of this disease is surgical removal
of the tumour including surgical staging. In the case of
unilateral disease and a desire to conceive, a macroscopi-
cally unsuspicious contralateral ovary with tube and uterus
can be preserved.
An ovary-damaging biopsy of the unsuspicious contra-
lateral ovary which has shown negative histology still
cannot reliably exclude that the ovary is actually affected,
therefore this surgical procedure is not recommended. In
the case of bilateral tumours, ovary-preserving extirpation
is justifiable, after discussing the increased risk of relapse
with the patient.
Fertility protection options
According to a review of the studies published up to now,
the risk of relapse of a borderline tumour after ovarian
stimulation treatment was 19.4% (n = 12/62) [37]. How-
ever, none of these relapses resulted in death. Nevertheless,
the patient should be informed that stimulation treatment
maybe associated with an increased risk of relapse.
Cryopreservation of ovarian tissue is recommended by
several teams in the international literature [38]. If the
tissue is to be retransplanted at a later date, however re-
transplantation of borderline tissue or the de novo devel-
opment of a borderline tumour cannot be excluded. The
patients must be informed about this risk accordingly and
only tissue with a high probability of not containing any
borderline tissue should be cryoconserved.
In principle, a pregnancy spontaneously occurring after
fertility preservation surgery or ovarian stimulation is
preferable to cryopreservation of ovarian tissue so that the
ovarian reserve is not further reduced by the removal of
ovarian tissue.
The network FertiPROTEKT
FertiPROTEKT (www.fertiprotekt.eu) was introduced in
2006 and is a network of around 70 university based,
hospital based and private infertility and oncology centres.
Its main goal is the nationwide introduction of local fer-
tility preservation programmes in Germany, Switzerland
and Austria, involving such techniques which give the
patients the highest chance to achieve a pregnancy. The
techniques—performed separately or in combination—are
those which can be performed by most of the infertility
centres and associated hospitals such as transposition of the
ovaries, ovarian stimulation, cryopreservation of oocytes,
zygotes and embryos as well as cryopreservation of ovarian
tissue and application of GnRH-agonists. Purely experi-
mental techniques such as xenotransplantation of ovarian
tissue and techniques which are apparently only successful
in specialized centres such as In vitro Maturation are
therefore not considered. Techniques, requiring highly
sophisticated expertise such as cryopreservation of ovarian
tissue are performed by only a few centres which fulfill
certain quality criteria.
A further goal of the network is to train all involved
centres in fertility preservation techniques and to perform
quality control procedures.
All network members need to attend the annual con-
ference of the network and must provide data for a register
about their fertility preservation treatments, and the
resulting pregnancies. These data and the number of
treatments per centre are published on the website of the
network to allow patients to choose those centres with the
highest experience.
The network also provides information about treatments,
its centres, etc. on bilingual (German and English) website
(http://www.fertiprotekt.eu). Around 7,000 website hits are
registered every month.
The recommendations described in this article have been
prepared by different specialists including infertility spe-
cialists and oncologists. They had been circulated among
all member of the network and have been discussed in
detail at the annual conferences among the around 100
participants in detail. The recommendations were adapted
according to the suggestions and were finalised by a board
of infertility specialists and oncologists.
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